B-type natriuretic peptide is an important prognostic marker in heart failure. However, there are limited data for its value in non-cardiac intensive care unit patients, namely regarding long-term prognosis. We investigated the long-term prognostic value of BNP in a cohort of critically ill patients. This was a prospective and observational study, conducted in a tertiary university hospital 20-bed intensive care unit. We included 103 mechanically- ventilated patients admitted for a noncardiac primary diagnosis; B-type natriuretic peptide samples were obtained on admission. A mean 14 (3-30) month follow up was available in 96.1% of patients who were discharged from hospital. Mean age was 60.7±19.0 years and mean APACHE II score was 16.2±7.2. APACHE II score and renal dysfunction increased with rising B-type natriuretic peptide, with more than 60% of patients having Btype natriuretic peptide levels of 100 pg/mL or over; echocardiography-derived left ventricular ejection fraction was lower in patients with higher B-type natriuretic peptide (P < 0.001). Long-term survivors had lower median B-type natriuretic peptide values (117.5[2-1668] pg/mL) compared with intensive care unit non-survivors (191.0[5-4945] pg/mL), P<0.001. After adjustment to APACHE II score, B-type natriuretic peptide levels of 300 pg/mL or over were independently associated with long-term mortality (odds-ratio 4.1 [95% CI 1.45-11.5], P=0.008). We conclude that in an unselected cohort of intensive care unit patients, admission B-type natriuretic peptide is frequently elevated, even without clinically apparent acute heart disease, and is a strong independent predictor of long-term mortality.
BNP, critical illness, prognosis, mortality.
Rui Baptista Cardiology Department, Coimbra University Hospital and Medical School Praceta Mota Pinto, 3000-001 Coimbra, Portugal. Tel: + 351.918523940. E-mail: firstname.lastname@example.org
We are indebted to the ICU
nursing staff, for substantial help in blood sample
withdrawal and processing.
Share this Article
Related Content In Heart Failure
Natriuretic Peptide-guided Therapy for Heart Failure
Heart International. 2022;16(2):112–6 DOI: https://doi.org/10.17925/HI.2022.16.2.112
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1 Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac biomarkers reflect the pathophysiology of HF, they add information to the clinical findings.1 The most widely used […]
Comparison of Speckle Tracking Echocardiography During Different Pacing Modalities for Cardiac Resynchronization Therapy Response Prediction
Heart International. 2022;16(1):64–70 DOI: https://doi.org/10.17925/HI.2022.16.1.64
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (RV) pacing (RVP) system upgrade.1 The recommendations for CRT typically follow failure to improve after 3 […]
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!